Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Current Leases (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Current Leases for 6 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 56.83% to $7.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 56.83% increase, with the full-year FY2025 number at $7.2 million, up 56.83% from a year prior.
  • Current Leases was $7.2 million for Q4 2025 at TScan Therapeutics, up from $6.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $7.2 million in Q4 2025 to a low of $1.6 million in Q2 2021.
  • A 5-year average of $3.7 million and a median of $3.7 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 143.79% in 2023, then decreased 14.14% in 2024.
  • TScan Therapeutics' Current Leases stood at $1.7 million in 2021, then skyrocketed by 122.96% to $3.7 million in 2022, then dropped by 11.82% to $3.2 million in 2023, then soared by 40.79% to $4.6 million in 2024, then soared by 56.83% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Current Leases are $7.2 million (Q4 2025), $6.9 million (Q3 2025), and $6.3 million (Q2 2025).